The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
EP: 1.Patient Scenario: A 63-Year-Old Man with Multiple Myeloma
EP: 2.Resources for Educating Patients with Myeloma
EP: 3.Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM
EP: 4.Treatment Sequencing and the Role of Talquetamab in MM
EP: 5.Educating Patients on Adverse Effects Related to Talquetamab in MM
EP: 6.Managing Talquetamab-Associated Toxicities in Patients with MM
Now Viewing
EP: 7.The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
EP: 8.MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab
EP: 9.Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
